ONCT Oncternal Corp Earnings per share for the last twelve months

ONCT (Oncternal Therapeutics Inc) - company brandmark

Oncternal Therapeutics (ONCT) is currently restructuring its R&D priorities, which has created a temporary lull in innovation. On GURU.Markets, the annual net income per share chart visualizes this period, where the value -11.70 represents the current figure. The company's revenues are based on leukemia treatment partnerships, while financial stability relies on the success of zilovertamab and available capital.

ONCT (Oncternal Therapeutics) Net earnings per share for the last 12 months history from 07/04/2022 to 12/14/2024

Oncternal Corp - analytical breakdowns and key metrics (ONCT)

- current quotes and average value forecast:
Basic company analysis:oncternal.com (ONCT)
Mass-produced product of Oncternal

Selecting assets with a high margin of safety begins with an analysis of return on equity. Net income per share over 12 months measures the business's bottom-line earnings distributed across the total volume of issuance. For Oncternal Therapeutics (ONCT), this metric reflects the efficiency of antibody supply optimization and protection against logistical shocks. The trend in net income per share over 12 months reveals the impact of costs on margins. It is critical for investors to correlate this trend with the company's debt load.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|PRTG (Portage Biotech) - Earnings per one share for the last 12 months